Oslo, 7 September 2021 - Navamedic ASA (OSE: NAVA) receives approval for
conditional reimbursement for Mysimba® in Finland from 1 November 2021. The
company expects accelerated growth of Mysimba® in the Finnish market following
the reimbursement, further fueled by Navamedic's successful patient support
program planned for launch in Finland in 2022.

Mysimba® is the first obesity treatment of its kind, combining both an oral
medicin with a digital and custom-made patient support program to maximise
patients' success in treatment. Mysimba® reduces hunger and cravings, and
provides control over food intake, while the patient support program provides
help in lifestyle and behavioural change for patients throughout the treatment
period.

"We are pleased to announce that we have received approval for conditional
reimbursement for Mysimba in Finland. Navamedic is looking forward to expanding
the availability of this unique medicine to the Finnish population," says
Kathrine Gamborg Andreassen, CEO of Navamedic ASA, and continues.

"Mysimba is one of the fastest growing products in our portfolio, displaying
sales growth of 89% in the first half of 2021 compared to the same period last
year. We have strong traction in both Norway, where we already have conditional
reimbursement, and in Sweden, where we have seen impressive results from our our
patient support program. Now we are looking forward to accelerate our growth of
Mysimba in the Finnish market, further fueled by strong support from local key
opinion leaders."

According to the World Health Organization, around 13% of the world's population
suffer from obesity, defined as abnormal or excessive fat accumulation that
presents a risk to health, with a Body Mass Index (BMI) above 30. Obesity is a
contributing risk factor for diseases such as cardiovascular diseases, diabetes
and some cancers. According to Navamedic's estimates, around 900 000 people in
Finland are obese.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visit www.navamedic.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.